Celgene shares rose more than
5% in value yesterday on the news
that the company had secured
a deal to buy biopharmaceutical
company Receptos, whose shares
jumped as high as 11% according to
a report by CNBC.
Reported to be worth US$7.2
billion the deal will see Celgene
grow its inflammation and
immunology portfolio, with
implications for inflammatory
bowel disease and multiple
sclerosis treatments.
Receptos’ lead product,
ozanimod, has shown positive signs
in the treatment of ulcerative colitis
and relapsing multiple sclerosis.The above article was sent to subscribers in Pharmacy Daily's issue from 16 Jul 15 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 16 Jul 15
DEMENTIA Australia has appointed comedian Geraldine Hickey (pictured) as its newest Ambassador, coinciding with the Melbourne Memory Walk & Jog event taking place this Sun.
NEW research from the Monash Addiction Research Centre has highlighted a critical shortfall in the availability of Naloxone, a life-saving medication that reverses opioid overdoses, across community pharmacies in Australia’s most populous states.
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.